139 related articles for article (PubMed ID: 38485147)
21. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
McCarthy C; Brewington JJ; Harkness B; Clancy JP; Trapnell BC
Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29563174
[No Abstract] [Full Text] [Related]
22. G970R-CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect.
Fidler MC; Buckley A; Sullivan JC; Statia M; Boj SF; Vries RGJ; Munck A; Higgins M; Moretto Zita M; Negulescu P; van Goor F; De Boeck K
Clin Transl Sci; 2021 Mar; 14(2):656-663. PubMed ID: 33278322
[TBL] [Abstract][Full Text] [Related]
23. Personalised medicine for non-classic cystic fibrosis resulting from rare CFTR mutations.
McCravy MS; Quinney NL; Cholon DM; Boyles SE; Jensen TJ; Aleksandrov AA; Donaldson SH; Noone PG; Gentzsch M
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32265312
[No Abstract] [Full Text] [Related]
24. Conclusion and Prospects: Genetics of cystic fibrosis - an agenda for the next ten years.
Castellani C
Arch Pediatr; 2020 Feb; 27 Suppl 1():eS45-eS47. PubMed ID: 32172938
[No Abstract] [Full Text] [Related]
25. A personalized medicine approach to optimize care for a pediatric cystic fibrosis patient with atypical clinical symptoms.
Lee J; Husami A; Arora K; Zhang W; Kadri F; Yarlagadda S; Moon C; Mun KS; Zhang K; Huang Y; Liyanage P; Brewington J; Clancy JP; Shaikhkhalil A; Paul G; Naren AP
Pediatr Pulmonol; 2024 Jan; 59(1):229-232. PubMed ID: 37818777
[No Abstract] [Full Text] [Related]
26. Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models.
Song Y; Sonawane ND; Salinas D; Qian L; Pedemonte N; Galietta LJ; Verkman AS
J Biol Chem; 2004 Sep; 279(39):40629-33. PubMed ID: 15280357
[TBL] [Abstract][Full Text] [Related]
27. A new era of personalized medicine for cystic fibrosis - at last!
Quon BS; Wilcox PG
Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
[TBL] [Abstract][Full Text] [Related]
28. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
Kaiser J
Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
[No Abstract] [Full Text] [Related]
29. CFTR regulation of intracellular calcium in normal and cystic fibrosis human airway epithelia.
Walsh DE; Harvey BJ; Urbach V
J Membr Biol; 2000 Oct; 177(3):209-19. PubMed ID: 11014859
[TBL] [Abstract][Full Text] [Related]
30. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene.
Du M; Jones JR; Lanier J; Keeling KM; Lindsey JR; Tousson A; Bebök Z; Whitsett JA; Dey CR; Colledge WH; Evans MJ; Sorscher EJ; Bedwell DM
J Mol Med (Berl); 2002 Sep; 80(9):595-604. PubMed ID: 12226741
[TBL] [Abstract][Full Text] [Related]
31. [Cystic fibrosis: From gene discovery to precision medicine].
Férec C
Med Sci (Paris); 2021; 37(6-7):618-624. PubMed ID: 34180821
[TBL] [Abstract][Full Text] [Related]
32. Rescue of epithelial HCO3- secretion in murine intestine by apical membrane expression of the cystic fibrosis transmembrane conductance regulator mutant F508del.
Xiao F; Li J; Singh AK; Riederer B; Wang J; Sultan A; Park H; Lee MG; Lamprecht G; Scholte BJ; De Jonge HR; Seidler U
J Physiol; 2012 Nov; 590(21):5317-34. PubMed ID: 22802588
[TBL] [Abstract][Full Text] [Related]
33. Involvement of the anion exchanger SLC26A6 in prostaglandin E2- but not forskolin-stimulated duodenal HCO3- secretion.
Tuo B; Riederer B; Wang Z; Colledge WH; Soleimani M; Seidler U
Gastroenterology; 2006 Feb; 130(2):349-58. PubMed ID: 16472591
[TBL] [Abstract][Full Text] [Related]
34. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator.
Poulsen JH; Fischer H; Illek B; Machen TE
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5340-4. PubMed ID: 7515498
[TBL] [Abstract][Full Text] [Related]
35. The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory Genistein binding site.
Derand R; Bulteau-Pignoux L; Becq F
J Biol Chem; 2002 Sep; 277(39):35999-6004. PubMed ID: 12124395
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic duct organoid swelling is chloride-dependent.
O'Malley Y; Zarei K; Vanegas OGC; Singh P; Apak TI; Coleman M; Thornell IM; Uc A
J Cyst Fibros; 2024 Jan; 23(1):169-171. PubMed ID: 37633792
[TBL] [Abstract][Full Text] [Related]
37. Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis.
Guimbellot JS; Nichols DP; Brewington JJ
Clin Chest Med; 2022 Dec; 43(4):617-630. PubMed ID: 36344070
[TBL] [Abstract][Full Text] [Related]
38. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening.
Ma T; Vetrivel L; Yang H; Pedemonte N; Zegarra-Moran O; Galietta LJ; Verkman AS
J Biol Chem; 2002 Oct; 277(40):37235-41. PubMed ID: 12161441
[TBL] [Abstract][Full Text] [Related]
39. How do cystic fibrosis transmembrane conductance regulator mutations produce lung disease?
Pilewski JM; Frizzell RA
Curr Opin Pulm Med; 1995 Nov; 1(6):435-43. PubMed ID: 9363079
[TBL] [Abstract][Full Text] [Related]
40. Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.
McCague AF; Raraigh KS; Pellicore MJ; Davis-Marcisak EF; Evans TA; Han ST; Lu Z; Joynt AT; Sharma N; Castellani C; Collaco JM; Corey M; Lewis MH; Penland CM; Rommens JM; Stephenson AL; Sosnay PR; Cutting GR
Am J Respir Crit Care Med; 2019 May; 199(9):1116-1126. PubMed ID: 30888834
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
